Herpes zoster in psoriasis patients treated with tofacitinib
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2017.03.023
Abstract: Background Tofacitinib is an oral Janus kinase (JAK) inhibitor. Immunomodulatory therapies can increase the risk for herpes zoster (HZ) in patients with psoriasis. Objective To evaluate the relationship between tofacitinib use and HZ risk. Methods… read more here.
Keywords: tofacitinib; risk; zoster psoriasis; herpes zoster ... See more keywords